Publication: Patterns of hydroxyurea prescription and use in routine clinical management of polycythemia vera: A multicenter chart review study
dc.contributor.author | Büyükaşık, Yahya | |
dc.contributor.author | Turgut, Mehmet | |
dc.contributor.author | Saydam, Güray | |
dc.contributor.author | Yavuz, Selim | |
dc.contributor.author | Ünal, Ali | |
dc.contributor.author | Ar, Muhlis Cem | |
dc.contributor.author | Ayyıldız, Orhan | |
dc.contributor.author | Altuntaş, Fevzi | |
dc.contributor.author | Okay, Mufide | |
dc.contributor.author | Çiftçiler, Rafiye | |
dc.contributor.author | Meletli, Özgür | |
dc.contributor.author | Soyer, Nur | |
dc.contributor.author | Mastanzade, Metban | |
dc.contributor.author | Güven, Zeynep | |
dc.contributor.author | Soysal, Teoman | |
dc.contributor.author | Karakuş, Abdullah | |
dc.contributor.author | Yiğenoğlu, Tuğce Nur | |
dc.contributor.author | Uçar, Barış | |
dc.contributor.author | Gökçen, Ece | |
dc.contributor.author | Tuğlular, Tülin | |
dc.contributor.buuauthor | Ali, Rıdvan | |
dc.contributor.buuauthor | ALİ, RIDVAN | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı. | |
dc.contributor.researcherid | GXD-8209-2022 | |
dc.date.accessioned | 2024-07-05T12:31:15Z | |
dc.date.available | 2024-07-05T12:31:15Z | |
dc.date.issued | 2020-01-01 | |
dc.description.abstract | Objective: This study aimed to evaluate real-life data on patterns of hydroxyurea prescription/use in polycythemia vera (PV).Materials and Methods: This retrospective chart review study included PV patients who had received hydroxyurea therapy for at least 2 months after PV diagnosis. Data were collected from 10 representative academic medical centers.Results: Of 657 patients, 50.9% were in the high-risk group (age 60 years and/or history of thromboembolic event). The median duration of hydroxyurea therapy was 43.40 months for all patients; 70.2% of the patients had ongoing hydroxyurea therapy at last followup. Hydroxyurea was discontinued in 22.4% of the patients; the most common reason was death (38.5%). The predicted time until hydroxyurea discontinuation was 187.8 months (standard error: +/- 21.7) for all patients. This duration was shorter in females (140.3 +/- 37.7 vs. 187.8 +/- 29.7) (p=0.08). This trend was also observed in surviving patients aged >= 50 years at hydroxyurea initiation (122.2 +/- 12.4 vs. 187.8 +/- 30.7, p=0.03). Among the patients who were still on hydroxyurea therapy, 40.3% had a hematocrit concentration of >= 45% at their last followup visit, and the rate of patients with at least one elevated blood cell count was 67.8%.Conclusion: Hydroxyurea prescription patterns and treatment aims are frequently not in accordance with the guideline recommendations. Its discontinuation rate is higher in females. | |
dc.identifier.doi | 10.4274/tjh.galenos.2020.2019.0431 | |
dc.identifier.endpage | 185 | |
dc.identifier.issn | 1300-7777 | |
dc.identifier.issue | 3 | |
dc.identifier.startpage | 177 | |
dc.identifier.uri | https://doi.org/10.4274/tjh.galenos.2020.2019.0431 | |
dc.identifier.uri | https://hdl.handle.net/11452/42994 | |
dc.identifier.volume | 37 | |
dc.identifier.wos | 000564138800005 | |
dc.indexed.wos | WOS.SCI | |
dc.language.iso | en | |
dc.publisher | Galenos Yayincilik | |
dc.relation.journal | Turkish Journal Of Hematology | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Essential thrombocythemia | |
dc.subject | Prognostic value | |
dc.subject | Criteria | |
dc.subject | Hydroxycarbamide | |
dc.subject | Intolerance | |
dc.subject | Resistance | |
dc.subject | Survival | |
dc.subject | Events | |
dc.subject | Risk | |
dc.subject | Eln | |
dc.subject | Polycythemia vera | |
dc.subject | Hydroxyurea | |
dc.subject | Treatment outcome | |
dc.subject | Science & technology | |
dc.subject | Life sciences & biomedicine | |
dc.subject | Hematology | |
dc.title | Patterns of hydroxyurea prescription and use in routine clinical management of polycythemia vera: A multicenter chart review study | |
dc.type | Review | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | 578cac50-ce4d-4818-8e99-2634ef340753 | |
relation.isAuthorOfPublication.latestForDiscovery | 578cac50-ce4d-4818-8e99-2634ef340753 |